Aromasin
(Exemestane)ApprovedSmall molecule
PfizerExemestane is used to treat hormone receptor-positive breast cancer in postmenopausal women. It works by blocking the production of estrogen, which can fuel the growth of certain breast cancers.[2] Aromasin is currently approved and in use across 29 indications[4].[1]
Aromasin is one of 435 small molecule programs targeting Bone Metastasis. It is currently in Approved.
29
Indications
204
Total Trials
41
Active Trials
434
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 29 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Aromasin
PfizerApproved
Lexiscan
AstellasPreclinical
Acupan
YYonsei University
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Paracetamol
GSKPreclinical
Zoladex
Luye Pharma Group Ltd.Preclinical
Fentanyl Citrate
IINSYS Therapeutics Inc
Preclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer151 trials
Show 148 more trials
Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002777·342 enrolled
Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer
Completed·—·Phase 2·NCT00810797·36 enrolled
ER Reactivation Therapy for Breast Cancer
Completed·—·Phase 2·NCT02188745·19 enrolled
PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer
Unknown status·—·Phase 2·NCT02917005·160 enrolled
Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer
Unknown status·OOrganisation for Oncology and Translational Research·Phase 2·NCT02025712·35 enrolled
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
Completed·—·Phase 2·NCT02648477·30 enrolled
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
Active, not recruiting·
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06957379·78 enrolled
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06957379·78 enrolled
A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）
Unknown status·—·Phase 3·NCT03137368·300 enrolled
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
Recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT05512364·220 enrolled
Breast Cancer, Sexuality and Black Cohosh
Unknown status·IIrmandade da Santa Casa de Misericordia de Sao Paulo·Phase 4·NCT02467686·60 enrolled
Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Completed·—·Phase 2·NCT01594216·25 enrolled
Postmenopausal Women5 trials
Endocrine Therapy3 trials
Ovarian Cancer2 trials
32 more indications
TED2 trials
Non-Small Cell Lung Cancer2 trials
Steroid2 trials
Menopausal Women2 trials
Intraepithelial Neoplasia1 trial
Randomized1 trial
Observational Study1 trial
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
Unknown status·—··NCT04852081·1,000 enrolled
Patient Preference1 trial
Prostate Cancer1 trial
Bone Metastasis1 trial
Metastatic Solid Tumors1 trial
Ductal Carcinoma in Situ1 trial
Pancreatic Cancer1 trial
Tic Disorder1 trial
Ovarian Granulosa Cell Tumor1 trial
Prevention1 trial
Prospective1 trial
Endometrial Carcinoma1 trial
Exemestane in Advanced and Recurrent Endometrial Carcinoma
Completed·NNordic Society of Gynaecological Oncology - Clinical Trials Unit·Phase 2·NCT01965080·52 enrolled
Malignant Neoplasm1 trial
Anatomic Stage II Breast Cancer AJCC v81 trial
Metastatic Breast Cancer1 trial
Early Breast Cancer1 trial
Breast Neoplasms1 trial
Breast Adenocarcinoma1 trial
Anatomic Stage 0 Breast Cancer AJCC v81 trial
Breast Ductal Carcinoma in Situ1 trial
Unspecified2 trials
Palbociclib With Everolimus + Exemestane In BC
Completed·—·Phase 1/2·NCT02871791·41 enrolled
Regulatory
FDA Approval Timeline[5]
Oct 21, 1999
AROMASIN
NDA NDA020753
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Aromasin drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Exemestane. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]